Equities Analysts Offer Predictions for OKUR FY2025 Earnings

OnKure Therapeutics, Inc. (NASDAQ:OKUR) – Investment analysts at Lifesci Capital boosted their FY2025 EPS estimates for shares of OnKure Therapeutics in a research note issued on Wednesday, August 13th. Lifesci Capital analyst S. Slutsky now forecasts that the company will earn ($4.75) per share for the year, up from their prior forecast of ($4.80). The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share.

Separately, Evercore ISI started coverage on shares of OnKure Therapeutics in a report on Wednesday, April 30th. They set an “outperform” rating for the company. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $32.33.

OnKure Therapeutics Stock Performance

NASDAQ:OKUR opened at $2.53 on Friday. The company has a 50-day moving average of $2.41 and a 200-day moving average of $3.33. The company has a market capitalization of $34.18 million, a price-to-earnings ratio of -0.53 and a beta of 0.40. OnKure Therapeutics has a 52 week low of $1.70 and a 52 week high of $20.00.

OnKure Therapeutics (NASDAQ:OKUR) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.09.

Hedge Funds Weigh In On OnKure Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new position in OnKure Therapeutics during the 2nd quarter valued at about $25,000. Bailard Inc. acquired a new stake in OnKure Therapeutics in the 2nd quarter valued at about $34,000. ADAR1 Capital Management LLC acquired a new stake in OnKure Therapeutics in the 1st quarter valued at about $43,000. Rangeley Capital LLC acquired a new stake in OnKure Therapeutics in the 2nd quarter valued at about $71,000. Finally, Barclays PLC acquired a new stake in OnKure Therapeutics in the 4th quarter valued at about $75,000. 90.98% of the stock is owned by institutional investors.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.